| human | Q5 |
| P227 | GND ID | 173427057 |
| P496 | ORCID iD | 0000-0002-0775-138X |
| P1153 | Scopus author ID | 7003462047 |
| P214 | VIAF ID | 237908577 |
| P108 | employer | Antoni van Leeuwenhoekziekenhuis | Q2536586 |
| Benaroya Research Institute | Q4886865 | ||
| Agendia | Q30284525 | ||
| P734 | family name | Glas | Q16738572 |
| Glas | Q16738572 | ||
| Glas | Q16738572 | ||
| P106 | occupation | researcher | Q1650915 |
| Q87873895 | A Computational Workflow Translates a 58-Gene Signature to a Formalin-Fixed, Paraffin-Embedded Sample-Based Companion Diagnostic for Personalized Treatment of the BRAF-Mutation-Like Subtype of Colorectal Cancers |
| Q33843780 | A breast cancer gene signature for indolent disease |
| Q37578778 | A gene expression profile for detection of sufficient tumour cells in breast tumour tissue: microarray diagnosis eligibility |
| Q57937919 | Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival |
| Q44874206 | B-cell-autonomous somatic mutation deficit following bone marrow transplant. |
| Q41104339 | Biological functions of the genes in the mammaprint breast cancer profile reflect the hallmarks of cancer. |
| Q38800922 | Characterisation of multifocal breast cancer using the 70-gene signature in clinical low-risk patients enrolled in the EORTC 10041/BIG 03-04 MINDACT trial |
| Q43181563 | Clinical utility of the 70-gene MammaPrint profile in a Japanese population. |
| Q42839175 | Comparison of MammaPrint and TargetPrint results with clinical parameters in German patients with early stage breast cancer. |
| Q97905185 | Controlling technical variation amongst 6693 patient microarrays of the randomized MINDACT trial |
| Q33262104 | Converting a breast cancer microarray signature into a high-throughput diagnostic test. |
| Q41527706 | DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial |
| Q90077881 | Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris |
| Q34519347 | Equivalence of MammaPrint array types in clinical trials and diagnostics |
| Q56601042 | Gene Expression Signature to Improve Prognosis Prediction of Stage II and III Colorectal Cancer |
| Q79188315 | Gene expression profiles of primary breast carcinomas from patients at high risk for local recurrence after breast-conserving therapy |
| Q81996222 | Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary |
| Q37625239 | Gene expression profiling: decoding breast cancer. |
| Q53338355 | Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. |
| Q37671966 | High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial |
| Q42515438 | Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial. |
| Q37926544 | Impact of mammographic screening on the detection of good and poor prognosis breast cancers |
| Q51819389 | Implementation of a novel microarray-based diagnostic test for cancer of unknown primary. |
| Q94355975 | Lymph node metastases display gene expression profiles of their primary breast carcinomas |
| Q92586787 | MammaPrint and BluePrint Molecular Diagnostics Using Targeted RNA Next-Generation Sequencing Technology |
| Q46046002 | MammaPrint molecular diagnostics on formalin-fixed, paraffin-embedded tissue |
| Q62030172 | Mechanisms and Effects of Loss of Human Leukocyte Antigen Class II Expression in Immune-Privileged Site-Associated B-Cell Lymphoma |
| Q59565565 | Molecular Portraits and 70-Gene Prognosis Signature Are Preserved throughout the Metastatic Process of Breast Cancer |
| Q50222956 | Molecular prediction of tamoxifen resistance in breast cancer. |
| Q30637151 | Motif-specific probes identify individual genes and detect somatic mutations. |
| Q37376167 | Neoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferation. |
| Q36615425 | No common denominator for breast cancer lymph node metastasis |
| Q45097834 | Non-stochastic utilization of Ig V region genes in unselected human peripheral B cells. |
| Q57541319 | Performance characteristics of the MammaPrint®breast cancer diagnostic gene signature |
| Q40374426 | Polymorphism and utilization of human VH Genes. |
| Q79846956 | Primary testicular diffuse large B-cell lymphomas have activated B-cell-like subtype characteristics |
| Q59567583 | The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1–3 positive lymph nodes in an independent validation study |
| Q41542872 | The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting. |
| Q52194040 | The human heavy chain Ig V region gene repertoire is biased at all stages of B cell ontogeny, including early pre-B cells. |
| Q45105020 | VH repertoire in human B lymphocytes stimulated by CD40 ligand and IL-4: evidence for positive and negative selection mechanisms coupled to CD40 activation. |
| Q82083040 | Validation of 70-gene prognosis signature in node-negative breast cancer |
| Q73154674 | Very late relapse in diffuse large B-cell lymphoma represents clonally related disease and is marked by germinal center cell features |
Search more.